Epiminder Limited reported a $42.7 million loss for FY26, driven by clinical trial and product development costs following a $125 million IPO. The company progresses its FDA-approved Minder implantable EEG monitor with a pivotal US trial and next-gen device on track for 2028 launch.
- FY26 loss widens 34% to $42.7 million
- $125 million IPO completed in December 2025
- 50 patients enrolled in US DETECT trial by July 2026
- Next-generation Minder device design near completion
- Cash reserves of $75.8 million to fund operations into 2028
Loss Deepens Amid Major Commercial Push
Epiminder Limited (ASX:EPI) posted a $42.7 million loss for the year ended 30 June 2026, a 34% increase from the prior year’s $31.8 million deficit. The widening loss reflects ramped-up research, clinical trial expenses, and development costs as the company accelerates commercialisation of its FDA-cleared Minder implantable Continuous Epilepsy Monitor (iCEM®).
Despite the loss, Epiminder’s balance sheet strengthened significantly after its $125 million initial public offering (IPO) in December 2025, which eliminated debt and provided a robust war chest to fund its growth plans. Cash and term deposits stood at $75.8 million at year-end, expected to sustain operations well into calendar 2028.
Clinical Trial Progress Fuels US Market Entry
The company’s primary commercial catalyst is the ongoing DETECT (Diagnosing Epilepsy to Effect Change) trial, a post-approval study enrolling up to 210 patients across 25 leading US epilepsy centres. By mid-July 2026, 50 patients had been implanted with the Minder device, with 20 centres actively participating, including Harvard, Stanford, Yale, Mayo Clinic, and Duke.
This trial aims to generate the clinical and economic evidence necessary to secure reimbursement from US public and private payers, building on the earlier Australian UMPIRE study that demonstrated actionable clinical insights in 88% of participants. The DETECT trial’s progress is a critical step toward full commercialisation targeted for the first half of 2028. This momentum aligns with a Medicare reimbursement pathway already established, including a proposed 14% payment increase for 2027, underscoring growing payer recognition.
Next-Generation Device Nears Completion
Parallel to the clinical rollout, Epiminder is developing a next-generation Minder system designed to be slimmer, more cost-effective, and technologically advanced with improved battery life and communication capabilities. The design is well advanced, with approximately 200 devices manufactured for biocompatibility and functional testing.
The company plans to seek FDA clearance for this iteration under the 510(k) pathway, leveraging the original FDA-approved device as a predicate to streamline approval. Full commercial launch of the next-gen device is anticipated in the first half of 2028, which will underpin Epiminder’s broader market expansion.
IPO Funds Drive Strategic Milestones and Governance
The December 2025 IPO also enabled Epiminder to settle $15.8 million in historical research and development rebate claims with the Australian Taxation Office and clear all outstanding convertible notes. The company emerged debt-free with a strengthened capital base to execute its commercialisation plan.
On the governance front, the company formalised its remuneration framework post-listing, aligning executive incentives with strategic milestones such as DETECT progress and next-gen device development. CEO Rohan Hoare earned 91% of his short-term incentive for FY26, reflecting strong delivery against these objectives. The Board remains focused on maintaining prudent capital management while driving clinical and commercial milestones.
Market Opportunity and Strategic Risks
Epiminder targets the US drug-resistant epilepsy market, estimated at 1.1 million adults lacking reliable long-term seizure monitoring. The company positions Minder as a first-in-class, sub-scalp EEG system capable of continuous monitoring for up to three years, offering clinicians objective seizure data to improve diagnosis and treatment.
Key risks include the successful completion of the DETECT trial and reimbursement adoption, regulatory approvals for the next-gen device, and reliance on third-party manufacturing partnerships, notably with Cochlear Limited, which holds a 36% stake and supplies manufacturing capacity.
With no revenues yet, the company’s path to profitability hinges on clinical validation, payer acceptance, and commercial execution over the next two years.
Bottom Line?
Epiminder’s FY26 results underline the heavy investment phase ahead of commercial revenue; upcoming DETECT trial milestones and next-gen device FDA clearance will be pivotal in validating its long-term growth trajectory.
Questions in the middle?
- Will the DETECT trial deliver the clinical and economic evidence required for broad US reimbursement?
- How will the next-generation Minder device’s FDA approval timeline impact the planned 2028 commercial launch?
- What risks does reliance on Cochlear Limited for manufacturing pose as Epiminder scales production?